TEE
KPTI icon

Tibra Equities Europe’s Karyopharm Therapeutics KPTI Stock Holding History

Tibra Equities Europe’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,953
Closed -$282K – 253
2019
Q3 		$282K Buy
+1,953
New +$265K 0.03% 188

Other funds holding KPTI

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tibra Equities Europe's KPTI Position: Q4 2019 in Review

Tibra Equities Europe sold out of Karyopharm Therapeutics (KPTI) in Q4 2019, closing a stake of 1,953 shares — an estimated $282K sold.

Tibra Equities Europe first reported a position in KPTI in Q3 2019 and held it in 1 quarter. The position peaked at $282K in Q3 2019. 146 funds tracked by Wall St. Rank hold KPTI as of Q4 2019.

  • Tibra Equities Europe reported no remaining Karyopharm Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 1,953 Karyopharm Therapeutics shares in Q4 2019, an estimated $282K.
  • Tibra Equities Europe first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 1 quarter.
  • Tibra Equities Europe's Karyopharm Therapeutics position peaked at $282K in Q3 2019.
  • 146 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2019.

Based on Tibra Equities Europe's 13F filing for Q4 2019, filed 14 Feb 2020.